Back to results
US 2016/0101073 A1Published application
Composition for reducing frequency of urination, methrod of making and use thereof
AssigneeWellesley Pharmaceuticals, LLC
InventorDavid A. DILL
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.
Claims50
A method for manufacturing a pharmaceutical composition for reducing the frequency of urination, comprising:
- forming a first mixture comprising a first active ingredient formulated for immediate release and a second active ingredient formulated for extended release;
- coating the first mixture with a delayed release coating to form a core structure;
- coating the core structure with a second mixture comprising a third active ingredient formulated for immediate release and a fourth active ingredient formulated for extended release,
- wherein at least one of the first, second, third and fourth active ingredients comprises a prostaglandin pathway inhibitor.
1 more element
A method for manufacturing a pharmaceutical composition for reducing the frequency of urination, comprising:
- forming a core structure comprising a first active ingredient formulated for immediate release and a second active ingredient formulated for extended release;
- coating the core structure with a delayed release coating to form a coated core structure;
- mixing the coated core structure with a third active ingredient formulated for immediate release and a fourth active ingredient formulated for extended release to form a final mixture;
- and
- preparing a dosage form with the final mixture,
- wherein at least one of the first, second, third and fourth active ingredients comprises a prostaglandin pathway inhibitor.
3 more elements
A method for manufacturing a pharmaceutical composition for reducing the frequency of urination, comprising:
- forming a core structure comprising a first active ingredient formulated for immediate release and a second active ingredient formulated for extended release;
- coating the core structure with a delayed release coating to form a coated core structure;
- coating the coated core structure with a third active ingredient formulated for extended release to form an extended-release layer coated core structure;
- and
- coating the extended-release layer coated core structure with a fourth active ingredient,
- wherein at least one of the first, second, third and fourth active ingredients comprises a prostaglandin pathway inhibitor.
3 more elements
A pharmaceutical composition, comprising:
- a first component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration;
- and
- a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents,
- wherein at least one of subcomponents in the first component or the second component comprises an active ingredient comprising a prostaglandin pathway inhibitor.
1 more element
A pharmaceutical composition, comprising:
- a first component comprising an immediate-release subcomponent, wherein the immediate-release subcomponent comprises an active ingredient comprising one or more agents selected from the group consisting of analgesic agents and prostaglandin pathway inhibitors, wherein the first component is formulated to release its subcomponent immediately after oral administration;
- and
- a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated to release its subcomponent after gastric emptying of the second component,
- wherein at least one of the subcomponents in the first or the second components comprises an active ingredient comprising one or more agents selected from the group consisting of analgesic agents and prostaglandin pathway inhibitors.
1 more element
A pharmaceutical composition, comprising:
- an immediate-release component comprising acetaminophen and an NSAID, each in an amount of 5-2000 mg;
- and
- an extended-release component comprising acetaminophen and an NSAID, each in an amount of 5-2000 mg,
- wherein the immediate-release component, or the extended-release component, or both, further comprise a prostaglandin pathway inhibitor.
1 more element
Dependencies are inferred from the claim text.